cytarabine

(redirected from Depocyt)

cytarabine

 [si-tar´ah-bēn]
an antimetaboliteantineoplastic agent that inhibits DNA polymerase and thus inhibits DNA synthesis during a specific phase of the cell cycle. Administered intravenously to treat acute myelogenous and other types of leukemia. It is also injected intrathecally to treat meningitis associated with leukemia or lymphoma. Called also cytosine arabinoside.

cytarabine

/cy·tar·a·bine/ (ara-C) (si-tar´ah-bēn) an antimetabolite that inhibits DNA synthesis and hence has antineoplastic properties; used in the treatment of acute myelogenous and other types of leukemia and of meningitis associated with leukemia or lymphoma.

cytarabine

(sī-tăr′ə-bēn′)
n.
A cytotoxic compound that inhibits DNA synthesis and is used as a chemotherapeutic agent, usually in combination with other drugs, in the treatment of certain types of leukemia.

cytarabine

[siter′əbēn]
an antineoplastic agent. Also called arabinosylcytosine, ARA-C, cytosine arabinoside.
indications It is prescribed in the treatment of acute and chronic myelocytic leukemia, acute lymphocytic leukemia, and erythroleukemia.
contraindication Known hypersensitivity to this drug prohibits its use.
adverse effects The most serious adverse reactions are bone marrow depression, stomatitis, phlebitis, liver toxicity, fever, and GI disturbances.

cytarabine

AraC, cytosine arabinoside Oncology An antimetabolite analogue of deoxycytidine, used synergistically with antifolates, alkylating agents, and cis-platinum to treat AML Pharmacokinetics Poorly absorbed–±20% absorbed orally, better IV; T1 ⁄ 2, ±2.5 hrs; 90% metabolized to the inactive arabinosyl uracil Side effects N&V, myelosuppression; in high doses, cerebral dysfunction, ataxia

cytarabine

An antimetabolite drug used in the treatment of acute LEUKAEMIA. It is a purine antagonist (see PURINES) and acts by depriving cells of essential metabolic substances. It causes sickness and vomiting, peptic ulcers and depression of bone marrow blood formation. The drug is on the WHO official list. A brand name is Cytosar.

cytarabine

an antimetabolite that inhibits DNA synthesis, and hence has antineoplastic and antiviral properties. Called also cytosine arabinoside, arabinosyl cytosine, ara-C.
References in periodicals archive ?
Over the past two decades, many nanoparticles such as Doxil (doxorubicin), Megace ES (megestrol acetate), Abraxane (paclitaxel), Myocet (doxorubicin), DepoCyt (liposomal cytarabine), and DaunoXome (daunorubicin citrate) have been approved as drug delivery systems for cancer therapy.
Its two marketable products are DepoCyt for treating cancer-related neoplastic meningitis and DepoDur for the treatment of post-operative pain.
Enzon plans to market Onco TCS through its entire North American sales force of approximately 60 people, which currently markets ABELCET, ONCASPAR, and DEPOCYT to the oncology market.
This growth is primarily attributed to the expected launch of Phase III pipeline candidates Marqibo (vincristine sulfate liposomes injection), GRASPA (asparaginase loaded into erythrocytes), recombinant asparaginase (asparaginase) and Depocyt (liposomal cytarabine) during the forecast period.
The products sold include the cancer drug Oncaspar, fungal infection treatment Abelcet, meningitis drug DepoCyt, and Adagen, which is used for severe combined immunodeficiency disease, or "Bubble Boy Disease.
We are confident that he is the ideal person to lead Pacira by enhancing the revenue opportunities of our existing commercial products, DepoDur and DepoCyt, optimizing the development and launch of our key asset, DepoBupivacaine, while further exploring the untapped promise of our proprietary drug delivery technologies.
I have already mentioned the launches and pending launches of Solaraze, DepoCyt and Xatral OD.
Chiron Corporation holds the marketing rights for DepoCyt in the U.
SkyePharma PLC (Nasdaq: SKYE; LSE: SKP) announced today that the marketing and distribution rights to Japan and Taiwan for DepoCyt (cytarabine liposome injection) have been granted to Nippon-Shinyaku Co Ltd.
More specifically, there will be an update on progress with Xatral OD, DepoCyt, Solaraze, Foradil DPI and DepoMorphine -- some of SkyePharma's most advanced products.
DepoCyt is the only FDA approved treatment for patients with lymphomatous meningitis, a serious disabling and potentially fatal complication of cancer.
Between January 2003 and December 2014, Paul Capital stand to receive 15% of the annual royalties and revenues from DepoMorphine and three other SkyePharma products, namely Xatral OD, Solaraze and DepoCyt up to an agreed ceiling.